Albireo Media News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Albireo media. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Albireo Media Today - Breaking & Trending Today
– Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by the FDA – – Company to host investor conference call on July 21 at 8:30 a.m. ET – BOSTON, July 20, 2021 (GLOBE NEWSWIRE) Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), which does not require refrigeration and is easily administered as a once-daily capsule or opened and sprinkled onto soft foods. Albireo is launching Bylvay immediately to accelerate availability for the patients and families impacted by PFIC. ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Albireo to Host Virtual Investor Commercial Day 2021 Albireo Pharma, Inc.January 7, 2021 GMT BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for odevixibat in progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease. ....